NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Orthofix International N.V. (NASDAQ:OFIX) (“Orthofix”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
“FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.”
On December 16, 2016, SeekingAlpha.com published a report revealing how the “FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.” The report also states that as of October 1, 2016 “the FDA just transferred the BGS down classification process to the specific department responsible for handling the down classification (the department of Orthopedics).” Following this news, Orthofix stock dropped harshly during intraday trading on December 16, 2016. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.